Mallinckrodt Q2 net sales $485M; Acthar Gel up 48.8%; combined FY25 guidance $3.57-3.62B

Keenova Therapeutics plc

2025-Q2 EPS reported -$1.28 revenue$905,000,000

Legacy Mallinckrodt net sales $485.1M, down 5.7% YoY but up 8.5% ex-Therakos divestiture.
Acthar Gel net sales surged 48.8% YoY to $175.1M; guidance raised to 20-30% growth.
Legacy Endo Q2 revenues $447.8M flat YoY; XIAFLEX up 9.4% to $138.6M.
Combined FY2025 guidance: net sales $3.57-3.62B, Adj. EBITDA $1.10-1.13B.
Par Health spin-off expected Q4 2025; FY2025 net sales guidance $1.72-1.75B.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.